[Hormonal therapy of cancer of the corpus uteri].
A complex clinico-morphological study on the effect of 17-hydroxyprogesterone-capronate was conducted in a group of 75 patients aged 27-69 (stage I-15; stage II-41; stage III-17 and stage IV-2 cases). Total dose for the whole course was 8.0-10.0. All patients underwent surgery after hormonotherapy. Uterine cavity (before and during hormonotherapy) and resected material were examined histologically and cytologically. It was shown that 17-hydroxy-progesterone-capronate is capable of antitumor effect and even complete regression is possible. Most antitumor effect was observed at the initial stages of malignant disease and in cases of well-differentiated tumor. The data obtained may be used in deciding whether 17-hydroxyprogesterone-capronate should be administered in conjunction with other measures or separately.
D000077713:17 alpha-Hydroxyprogesterone Caproate; D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D006908:Hydroxyprogesterones / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged; D011300:Preoperative Care; D045167:Progesterone Congeners / Q000008:administration & dosage / Q000627:therapeutic use*; D014594:Uterine Neoplasms / Q000188:drug therapy* / Q000601:surgery
D006908:Hydroxyprogesterones; D045167:Progesterone Congeners; D000077713:17 alpha-Hydroxyprogesterone Caproate
Gormonal'naia terapiia raka tela matki.